Articles by Seymour Katz

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

Reinisch, Walter; de Villiers, Williem; Bene, László; More

Inflammatory Bowel Diseases. 16(2):233-242, February 2010.

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

Sands, Bruce E.; Kozarek, Richard; Spainhour, Jack; More

Inflammatory Bowel Diseases. 13(1):2-11, January 2007.

A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

Burakoff, Robert; Barish, Charles F.; Riff, Dennis; More

Inflammatory Bowel Diseases. 12(7):558-565, July 2006.